What is Integra LifeSciences's tissue reconstruction — R&D?

Integra LifeSciences (IART) reported tissue reconstruction — R&D of $8.17M in Q2 2026.

What does tissue reconstruction — R&D mean?

This reflects the investment in innovation, clinical trials, and product development specifically for the Tissue Reconstruction portfolio. It indicates the company's commitment to long-term growth and maintaining a competitive edge in regenerative therapy markets.

Integra LifeSciences (IART) Tissue Reconstruction — R&D

Screener

Other segment segments

Specialty Surgery

$14.2M—

Similar metrics at other companies

BLCOPharmaceuticals — R&D

$27M+125%

BLCOSurgical — R&D

$12M0.0%

BHCDiversified — R&D

$3M0.0%

BHCInternational — R&D

$6M0.0%

BHCSalix — R&D

$19M+11.8%

ZYMEZanidatamab — R&D

$2.18M+45.3%

Other financials

Income statement

See full

Revenue$418.8M+0.8%

Gross profit$219.7M+5.0%

Operating income$19.3M+104%

Net income$4.5M+101%

EPS (diluted)$0.06+101%

Balance sheet

See full

Cash & equivalents$214.4M-1.6%

Total debt$2.0B+3.2%

Total equity$1.0B+0.5%

Total assets$3.6B-2.8%

Cash flow

See full

Operating cash flow$22.8M+156%

CapEx$12.3M-38.9%

Free cash flow$10.5M+193%

Valuation

See full

Market cap$1.33B+38.0%

Enterprise value$3.08B+16.2%

P/S0.8×+0.2×

Profitability

See full

Gross margin52.5%-0.1pp

Operating margin2.6%+1.3pp

Net margin-0.4%—

FCF margin3.8%-6.3pp

Returns & leverage

See full

Return on equity-0.7%—

Debt / equity1.9×+0.1×

Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.

Filed: Jul 29, 2026, 4:03 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000917520-26-000058

Dollars in thousands	Three Months Ended June 30, 2026 / Specialty Surgery	Three Months Ended June 30, 2026 / Tissue Reconstruction	Three Months Ended June 30, 2026 / Corporate and Other	Three Months Ended June 30, 2026 / Total	Six Months Ended June 30, 2026 / Specialty Surgery	Six Months Ended June 30, 2026 / Tissue Reconstruction	Six Months Ended June 30, 2026 / Corporate and Other	Six Months Ended June 30, 2026 / Total
Total revenue, net	$309,269	$109,492	—	$418,761	$592,404	$218,275	—	$810,679
Cost of goods sold	130,212	41,989	26,816	199,017	240,687	79,448	53,818	373,953
Research and development	14,200	8,169	1,884	24,253	26,053	15,701	6,000	47,754
Selling, general & administrative	75,983	40,394	56,059	172,436	153,664	83,920	113,087	350,671
Intangible asset amortization	—	—	3,770	3,770	—	—	7,546	7,546
Total cost and expenses	220,395	90,552	88,529	399,476	420,404	179,069	180,451	779,924
Operating income (loss)	88,874	18,940	(88,529)	19,285	172,000	39,206	(180,451)	30,755
Interest income				4,267				8,372

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's tissue reconstruction — R&D?: Integra LifeSciences (IART) reported tissue reconstruction — R&D of $8.17M in Q2 2026.
What does tissue reconstruction — R&D mean?: This reflects the investment in innovation, clinical trials, and product development specifically for the Tissue Reconstruction portfolio. It indicates the company's commitment to long-term growth and maintaining a competitive edge in regenerative therapy markets.